+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CAR T-Cell Therapy Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 180 Pages
  • February 2024
  • Region: Global
  • Expert Market Research
  • ID: 5941073

Global CAR T-Cell Therapy Market Outlook

The global CAR T-Cell therapy market size was valued at USD 2.5 billion in 2023, driven by increasing incidence of blood cancer across the globe. The market size is anticipated to grow at a CAGR of 15.2% during the forecast period of 2024-2032 to achieve a value of USD 9 billion by 2032.

CAR T-Cell Therapy: Introduction

CAR T-cell therapies are groundbreaking treatments in cancer care, leveraging modified patient T-cells to target and eradicate cancer cells. Predominantly used for blood cancers like leukemia and lymphoma, these personalized therapies are witnessing expansion into solid tumors. Despite high costs and infrastructure challenges, advancements in technology, regulatory support, and global research collaborations are driving the evolution and adoption of CAR T-cell therapies, marking a significant shift towards more tailored and effective cancer treatment options.

Key Trends in the Global CAR T-Cell Therapy Market

There's a growing incidence of blood cancers like acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), which are primary targets for CAR T-cell therapies. This increase is driving demand for effective and targeted treatment options.

Continuous research and development efforts are leading to technological advancements in CAR T-cell therapy. Improvements in gene editing technologies, manufacturing processes, and the development of next-generation CAR T-cells are enhancing the efficacy and safety profile of these therapies.

While CAR T-cell therapy has been predominantly used for hematological malignancies, there's a growing research focus on expanding its application to solid tumors. This involves overcoming challenges such as tumor microenvironment, T-cell trafficking, and antigen heterogeneity.

CAR T-cell therapy is at the forefront of the personalized medicine trend, as it involves customizing treatment based on the patient's own T-cells. This trend is gaining momentum with the increasing demand for tailored treatment approaches and the potential for better treatment outcomes.

Regulatory agencies are providing support in the form of fast-track approvals and designations for CAR T-cell therapies, especially for indications where there's a significant unmet medical need. This is encouraging more investments and research in the field.

Pharmaceutical companies, biotech firms, and research institutions are increasingly collaborating to pool resources, share expertise, and expedite the development of CAR T-cell therapies. These partnerships are crucial for navigating the complex research, regulatory, and commercialization landscape.

Despite the promising potential of CAR T-cell therapy, market access and reimbursement remain significant challenges. The high cost of therapy and the need for specialized healthcare infrastructure for administration are issues that stakeholders are striving to address.

While the adoption of CAR T-cell therapy has been more prevalent in developed regions like North America and Europe, emerging markets are also showing interest. Improvements in healthcare infrastructure, rising healthcare expenditure, and increasing awareness are contributing to the gradual adoption in these regions.

Global CAR T-Cell Therapy Market Segmentation

Market breakup by Drug Type

  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Lisocabtagene Maraleuce
  • Idecabtagene Vicleucel
  • Ciltacabtegene Autoleucel
  • Others

Market breakup by Antigen

  • CD19
  • BCMA
  • HER2
  • GD2
  • CD22
  • CD30
  • CD33
  • HER1
  • CLDN18

Market breakup by Application

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Multiple Myeloma
  • Glioblastoma
  • Sarcoma
  • Neuroblastoma
  • Acute Myeloid Leukemia
  • Breast Cancer
  • Pancreatic Cancer
  • Hepatocellular Carcinoma
  • Colorectal Cancer
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global CAR T-Cell Therapy Market Overview

In North America, the United States is leading the CAR T-cell therapy market. The presence of major pharmaceutical companies, advanced healthcare infrastructure, and high healthcare expenditure contribute to the region's dominant position. North America also benefits from strong regulatory support and a large number of ongoing clinical trials.

Europe is a significant market for CAR T-cell therapy, with several European countries adopting these advanced treatments. The market is supported by robust healthcare systems, substantial investment in research and development, and favorable regulatory frameworks. Countries like Germany, the UK, and France are at the forefront in terms of adoption and research.

Japan is witnessing rapid growth in the CAR T-cell therapy market. Factors such as increasing prevalence of cancer, improving healthcare infrastructure, and rising healthcare expenditure are driving the market. Countries are investing heavily in research and development and are also working on localizing the manufacturing of CAR T-cell therapies to reduce costs and improve accessibility.

Global CAR T-Cell Therapy Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Autolus Therapeutics
  • CARsgen Therapeutics Co.Ltd.
  • Juno Therapeutics, Inc.
  • Sorrento Therapeutics, Inc.
  • Bluebird bio, Inc.
  • CELGENE CORPORATION
  • Eureka Therapeutics Inc.
  • Avacta Life Sciences Ltd.
  • Calyxt Inc.
  • Celyad Oncology SA
  • Fortress Biotech, Inc
  • IMMUNE THERAPEUTICS, INC
  • Alaunos Therapeutics, Inc.
  • Novartis AG
  • Gilead Sciences, Inc.


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global CAR T-Cell Therapy Market Overview
3.1 Global CAR T-Cell Therapy Market Historical Value (2017-2023)
3.2 Global CAR T-Cell Therapy Market Forecast Value (2024-2032)
4 Global CAR T-Cell Therapy Market Landscape
4.1 Global CAR T-Cell Therapy Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global CAR T-Cell Therapy Product Landscape
4.2.1 Analysis by Drug Type
4.2.2 Analysis by Antigen Type
4.2.3 Analysis by Application
5 Global CAR T-Cell Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global CAR T-Cell Therapy Market Segmentation
6.1 Global CAR T-Cell Therapy Market by Drug Type
6.1.1 Market Overview
6.1.2 Axicabtagene Ciloleucel
6.1.3 Tisagenlecleucel
6.1.4 Brexucabtagene Autoleucel
6.1.5 Lisocabtagene Maraleuce
6.1.6 Idecabtagene Vicleucel
6.1.7 Ciltacabtegene Autoleucel
6.1.8 Others
6.2 Global CAR T-Cell Therapy Market by Antigen
6.2.1 Market Overview
6.2.2 CD19
6.2.3 BCMA
6.2.4 HER2
6.2.5 GD2
6.2.6 CD22
6.2.7 CD30
6.2.8 CD33
6.2.9 HER1
6.2.10 CLDN18
6.3 Global CAR T-Cell Therapy Market by Application
6.3.1 Market Overview
6.3.2 Acute Lymphocytic Leukemia
6.3.3 Chronic Lymphocytic Leukemia
6.3.4 Diffuse Large B-Cell Lymphoma (DLBCL)
6.3.5 Follicular Lymphoma
6.3.6 Mantle Cell Lymphoma
6.3.7 Multiple Myeloma
6.3.8 Glioblastoma
6.3.9 Sarcoma
6.3.10 Neuroblastoma
6.3.11 Acute Myeloid Leukemia
6.3.12 Breast Cancer
6.3.13 Pancreatic Cancer
6.3.14 Hepatocellular Carcinoma
6.3.15 Colorectal Cancer
6.3.16 Others
6.4 Global CAR T-Cell Therapy Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America CAR T-Cell Therapy Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe CAR T-Cell Therapy Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific CAR T-Cell Therapy Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Others
10 Latin America CAR T-Cell Therapy Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa CAR T-Cell Therapy Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by Year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding & Investment Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Autolus Therapeutics
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 CARsgen Therapeutics Co.Ltd.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Juno Therapeutics, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Sorrento Therapeutics, Inc.
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Bluebird bio, Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 CELGENE CORPORATION
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Eureka Therapeutics Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Avacta Life Sciences Ltd.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Calyxt Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Celyad Oncology SA
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Fortress Biotech, Inc
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 IMMUNE THERAPEUTICS, INC
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Alaunos Therapeutics, Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Novartis AG
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Gilead Sciences, Inc.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
18 Global CAR T-Cell Therapy Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • Autolus Therapeutics
  • CARsgen Therapeutics Co.Ltd.
  • Juno Therapeutics Inc.
  • Sorrento Therapeutics Inc.
  • Bluebird bio Inc.
  • CELGENE CORPORATION
  • Eureka Therapeutics Inc.
  • Avacta Life Sciences Ltd.
  • Calyxt Inc.
  • Celyad Oncology SA
  • Fortress Biotech Inc
  • IMMUNE THERAPEUTICS Inc
  • Alaunos Therapeutics Inc.
  • Novartis AG
  • Gilead Sciences Inc.

Methodology

Loading
LOADING...

Table Information